Editorial: Complement and Immunotherapeutics.

Okrój M, Volokhina E
Frontiers in immunology · 2021 · doi:10.3389/fimmu.2021.663459 · PMID:33717205 · PMC7943609
OA: gold CC-BY-4.0
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash+body, 2026-08-17 ⓘ

This editorial introduces a research topic on complement-targeting immunotherapeutics, summarizing articles that describe novel inhibitors, antibodies, and fusion proteins for treating conditions like SARS-CoV-2, arthritis, SLE, and cancer.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-17 · read from full text ⓘ

This editorial introduces a research topic collection focused on complement system immunotherapeutics, summarizing studies on targeted drugs for autoimmune diseases, cancer, and renal disorders. It highlights specific articles investigating complement inhibitors for conditions like systemic lupus erythematosus and atypical hemolytic uremic syndrome, alongside analyses of antibody mechanisms and nanoparticle interactions. The text also notes that chronic inflammation in endometriosis may stem from pathological complement activation, citing a prospect for complement inhibition as a therapeutic approach in this condition. Relevance to endometriosis: listed as one indication where complement inhibition is discussed as a potential therapeutic strategy, though the paper's main focus is broader complement immunotherapeutics.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 12,715 characters · extracted from oa-doi-fallback · 2 sections · click to expand

References

1. RicklinDHajishengallisGYangKLambrisJD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. (2010) 11:785–97. 10.1038/ni.1923 2. ReisESMastellosDCYancopoulouDRisitanoAMRicklinDLambrisJD. Applying complement therapeutics to rare diseases. Clin Immunol. (2015) 161:225–40. 10.1016/j.clim.2015.08.009 3. GavriilakiEBrodskyRA. Complementopathies and precision medicine. J Clin Invest. (2020) 130:2152–63. 10.1172/JCI136094 4. MaloneyDGGrillo-LopezAJWhiteCABodkinDSchilderRJNeidhartJAet al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. (1997) 90:2188–95. 5. RotherRPRollinsSAMojcikCFBrodskyRABellL. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. (2007) 25:1256–64. 10.1038/nbt1344 6. ReisESMastellosDCRicklinDMantovaniALambrisJD. Complement in cancer: untangling an intricate relationship. Nat Rev Immunol. (2018) 18:5–18. 10.1038/nri.2017.97 7. RicklinDMastellosDCReisESLambrisJD. The renaissance of complement therapeutics. Nat Rev Nephrol. (2018) 14:26–47. 10.1038/nrneph.2017.156 Summary

Keywords

complement, immunotherapy, rituximab, eculizumab, factor H, antibodies Citation Okrój M and Volokhina E (2021) Editorial: Complement and Immunotherapeutics. Front. Immunol. 12:663459. doi: 10.3389/fimmu.2021.663459 Received 02 February 2021 Accepted 04 February 2021 Published 24 February 2021 Volume 12 - 2021 Edited and reviewed by Francesca Granucci, University of Milano-Bicocca, Italy Updates Copyright © 2021 Okrój and Volokhina. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. *Correspondence: Marcin Okrój [email protected] Volokhina [email protected] This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-09-27T09:11:36.575535+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Per Europe PMC